“EFFICACY AND RISKS PROFILES OF ‘GLP-1 RECEPTOR AGONISTS’ IN TYPE 2 DIABETES AND OBESITY: A SYSTEMATIC REVIEW OF BENEFITS AND RISKS” (2025) Review Journal of Neurological & Medical Sciences Review, 3(5), pp. 300–324. doi:10.63075/fmkjkn28.